Search

EHA-PTHiT Hematology Mini Tutorial

Dates: April 12-13, 2021
Location: VIRTUAL
Chairs: I Hus (Poland), T Robak (Poland) & G Gaidano (Italy)

As a prelude to the full Tutorial planned for later this year, EHA and the Polish Society of Hematology and Transfusion (PTHiT) present a virtual 'mini…

Read more

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers

HARMONY Alliance: Progress in Using Big Data Technology to Achieve Better Outcomes for Patients with Blood Cancers: HARMONY Alliance is an unparalleled medicine offensive to battle blood cancers by using Big Data analyses.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

EHA-AAH Joint membership

We are pleased to inform that EHA and the Albanian Association of Hematology (AAH) have joined forces and are offering you the possibility of an EHA-AAH Joint Membership in 2023.

Read more

EHA-AHA Joint membership

We are pleased to inform that EHA and the Armenian Hematology Association (AHA) have joined forces and are offering you the possibility of an EHA-AHA Joint Membership in 2023.

Read more

EHA-SFH Joint membership

We are pleased to inform that EHA and the Société Française d’Hématologie (SFH) have joined forces and are offering you the possibility of an EHA-SFH Joint Membership in 2024.

Read more

EHA-SRH Joint membership

We are pleased to inform that EHA and the Societatea Română de Hematologie (SRH) have joined forces and are offering you the possibility of an EHA-SRH Joint Membership in 2023.

Read more

Wide Consensus Reached at Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine'

DUBLIN, March 25: Wide consensus emerged at the Irish Presidency Conference on ‘Innovation and Patient Access to Personalised Medicine’ on the need for radical change if Europe's approach to healthcare is to benefit from the potential of personalised medicine.

Read more